References
1-Bukiri H, Volkmann ER. Current advances in the treatment of systemic sclerosis. Curr Opin Pharmacol. 2022 Jun;64:102211. doi: 10.1016/j.coph.2022.102211. Epub 2022 Apr 18. PMID: 35447517; PMCID: PMC9466985.
2-Smeeta Gajendra, Richa Gupta, Ritu Gupta, and Lalit Kumar. Coexistence of scleroderma with multiple myeloma: a rare association. BMJ Case Rep. 2013. doi: 10.1136/bcr-2013-200639.PMCID: PMC3794227.PMID: 24022902
3- Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 2016 May 25;6:12-8. doi: 10.1016/j.bbacli.2016.05.004. PMID: 27331023; PMCID: PMC4900299.
4-Frank van den Hoogen, etal.2013 classification criteria for Systenic Slerosis. Arhtritis & Rheumatism 2013.Volume65.N.11.PP:2737-2747.
5- Korting GW, Gilfrich HJ, Meyer zum Buschenfelde KH. Scleroderma adultorum and multiple myeloma. Arch Dermatol Forsch  1974;2013:379–85.
6- Doyle JA, Connolly SM, Hoagland HC. Hematologic disease in scleroderma syndromes. Acta Derm Venereol  1985;2013:521–5
7-Ohta A, Uitto J, Oikarinen AI, et al. Paraproteinemia in patients with scleroderma. Clinical findings and serum effects on skin fibroblasts in vitro. J Am Acad Dermatol  1987;2013:96–107.
8-Hodak E, Tamir R, David M, et al. Scleroderma adultorum associated with IgG-kappa multiple myeloma—a case report .  Clin Exp Dermatol  1988;2013:271–4.
9-Rimon D, Lurie M, Storch S, et al. Cardiomyopathy and multiple myeloma. Complications of scleroderma adultorum. Arch Intern Med  1988;2013:551–3
10-Salisbury JA, Shallcross H, Leigh IM. Scleroderma of Buschke associated with multiple myeloma. Clin Exp Dermatol  1988;2013:269–70
11- Nakanishi H, Takehara K, Soma Y, et al. Atypical scleroderma associated with multiple myeloma. Dermatologica  1989;2013:176–8
12-Schmidt KT, Gattuso P, Messmore H, et al. Scleroderma and smoldering myeloma. J Am Acad Dermatol  1992;2013:319–21
13- Pujol JA, Bueno M, Fuertes MA, et al. Improvement of scleroderma associated with IgA multiple myeloma alter chemotherapy. Clin Exp Dermatol  1995;2013:149–52.
14-Valente L, Velho GC, Farinha F, et al. Scleroderma, acanthosis nigricans and IgA/kappa multiple myeloma. Ann Dermatol Venereol  1997;2013:537–9.
15-Bachleitner-Hofmann T, Machold K, Knobler R, et al. Marked and sustained improvement of systemic sclerosis following polychemotherapy for coexistent multiple myeloma. Clin Exp Rheumatol  2002;2013:85–8
16-Colovic M, Jurisic V, Bila J, et al. FGF-R3 and OPG expression in patient with multiple myeloma following systemic sclerosis: case report and review of the literature. Int J Hematol  2011;2013:228–31.
17- Ebata S, Yoshizaki-Ogawa A, Sato S, Yoshizaki A. New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. J Clin Med. 2022 Aug 8;11(15):4631. doi: 10.3390/jcm11154631. PMID: 35956246; PMCID: PMC9369903.
18- Oliver SJ, Kaplan G. Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide. Arthritis Rheum  1999;2013:S187.